LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Search

Sangamo Therapeutics Inc

Fermé

Secteur Soins de santé

0.72 -2.7

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.71

Max

0.73

Chiffres clés

By Trading Economics

Ventes

-7.4M

2M

BPA

-0.34

Employés

405

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+281.94 upside

Dividendes

By Dow Jones

Prochains Résultats

30 oct. 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.3M

114M

Ouverture précédente

3.42

Clôture précédente

0.72

Sentiment de l'Actualité

By Acuity

79%

21%

321 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Sangamo Therapeutics Inc Graphique

Actualités Associées

6 sept. 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept. 2024, 21:18 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept. 2024, 21:05 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept. 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 20:39 UTC

Résultats

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept. 2024, 20:35 UTC

Actualités

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept. 2024, 20:34 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept. 2024, 20:11 UTC

Actualités

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept. 2024, 19:51 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept. 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept. 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept. 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept. 2024, 18:27 UTC

Actualités

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept. 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept. 2024, 18:15 UTC

Actualités

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept. 2024, 18:12 UTC

Actualités

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept. 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept. 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept. 2024, 17:30 UTC

Actualités

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept. 2024, 17:27 UTC

Actualités

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept. 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 sept. 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 sept. 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept. 2024, 16:35 UTC

Résultats
Actions en Tendance

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept. 2024, 16:33 UTC

Acquisitions, Fusions, Rachats

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept. 2024, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Résultats

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept. 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 sept. 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Comparaison

Variation de prix

Sangamo Therapeutics Inc prévision

Objectif de Prix

By TipRanks

281.94% hausse

Prévisions sur 12 Mois

Moyen 2.75 USD  281.94%

Haut 5 USD

Bas 1 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

3

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

0.722 / 0.81Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

321 / 365Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.